100 related articles for article (PubMed ID: 24635598)
1. Editorial comment from Dr Szarvas to Functional polymorphisms in the matrix metalloproteinase genes and their association with bladder cancer risk and recurrence: a mini-review.
Szarvas T
Int J Urol; 2014 Aug; 21(8):753. PubMed ID: 24635598
[No Abstract] [Full Text] [Related]
2. Editorial comment from Dr Miyata to Functional polymorphisms in the matrix metalloproteinase genes and their association with bladder cancer risk and recurrence: a mini-review.
Miyata Y
Int J Urol; 2014 Aug; 21(8):754. PubMed ID: 24661273
[No Abstract] [Full Text] [Related]
3. Functional polymorphisms in the matrix metalloproteinase genes and their association with bladder cancer risk and recurrence: a mini-review.
Wieczorek E; Wasowicz W; Gromadzinska J; Reszka E
Int J Urol; 2014 Aug; 21(8):744-52. PubMed ID: 24635493
[TBL] [Abstract][Full Text] [Related]
4. Gene expression and prognosis in bladder cancer--real progress? Editorial on 'S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy'.
Symanowski JT; Kim ES
Ann Oncol; 2014 May; 25(5):919-20. PubMed ID: 24608197
[No Abstract] [Full Text] [Related]
5. Editorial comment from Dr Todenhöfer and Dr Schwentner to recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading.
Todenhöfer T; Schwentner C
Int J Urol; 2014 Oct; 21(10):973. PubMed ID: 24947315
[No Abstract] [Full Text] [Related]
6. Response to editorial comment from Dr Todenhöfer and Dr Schwentner to recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading.
Lodde M; Mian C; Mayr R; Comploj E; Trenti E; Melotti R; Campodonico F; Maffezzini M; Fritsche HM; Pycha A
Int J Urol; 2014 Oct; 21(10):974. PubMed ID: 24947451
[No Abstract] [Full Text] [Related]
7. Ultra-slow N-Acetyltransferase 2 Is Associated with Recurrence-free Time in Bladder Cancer Patients.
Selinski S; Gerullis H; Otto T; Roth E; Volkert F; Ovsiannikov D; Salem J; Moormann O; Geis BC; Niedner H; Blaszkewicz M; Hengstler JG; Golka K
Eur Urol; 2017 Jun; 71(6):994-995. PubMed ID: 28040354
[No Abstract] [Full Text] [Related]
8. Editorial comment from Dr Borkowska to recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading.
Borkowska EM
Int J Urol; 2014 Oct; 21(10):974-5. PubMed ID: 24976179
[No Abstract] [Full Text] [Related]
9. MMP, VEGF and TIMP as prognostic factors in recurring bladder cancer.
Wieczorek E; Jablonowski Z; Tomasik B; Konecki T; Jablonska E; Gromadzinska J; Fendler W; Sosnowski M; Wasowicz W; Reszka E
Clin Biochem; 2015 Dec; 48(18):1235-40. PubMed ID: 26197083
[TBL] [Abstract][Full Text] [Related]
10. Editorial comment.
Gonzalgo ML
J Urol; 2009 Sep; 182(3):913. PubMed ID: 19616241
[No Abstract] [Full Text] [Related]
11. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness.
Kader AK; Liu J; Shao L; Dinney CP; Lin J; Wang Y; Gu J; Grossman HB; Wu X
Clin Cancer Res; 2007 May; 13(9):2614-20. PubMed ID: 17473191
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of matrix metalloproteinases in bladder carcinoma: a systematic review and meta-analysis.
Miao C; Liang C; Zhu J; Xu A; Zhao K; Hua Y; Zhang J; Chen W; Suo C; Zhang C; Liu Y; Su S; Wang Z
Oncotarget; 2017 May; 8(19):32309-32321. PubMed ID: 28427222
[TBL] [Abstract][Full Text] [Related]
13. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M
Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase expression in the recurrence of superficial low grade bladder transitional cell carcinoma.
Choi YD; Cho NH; Ahn HS; Cho KS; Cho SY; Yang WJ
J Urol; 2007 Mar; 177(3):1174-8. PubMed ID: 17296440
[TBL] [Abstract][Full Text] [Related]
15. TERT mutations in urine could predict bladder cancer recurrence.
Gourd E
Lancet Oncol; 2017 Aug; 18(8):e443. PubMed ID: 28712514
[No Abstract] [Full Text] [Related]
16. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer.
Kim SK; Roh YG; Park K; Kang TH; Kim WJ; Lee JS; Leem SH; Chu IS
Clin Cancer Res; 2014 Jun; 20(12):3233-43. PubMed ID: 24714775
[TBL] [Abstract][Full Text] [Related]
17. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
[TBL] [Abstract][Full Text] [Related]
18. Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary survivin.
Kenney DM; Geschwindt RD; Kary MR; Linic JM; Sardesai NY; Li ZQ
Tumour Biol; 2007; 28(2):57-62. PubMed ID: 17259754
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Global Histone Acetylation Levels in Bladder Cancer Patients.
Ellinger J; Schneider AC; Bachmann A; Kristiansen G; Müller SC; Rogenhofer S
Anticancer Res; 2016 Aug; 36(8):3961-4. PubMed ID: 27466500
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of ESCO1 is correlated with poor patient survival and its role in human bladder cancer.
Zhang S; Li J; Zhou G; Mu D; Yan J; Xing J; Yao Z; Sheng H; Li D; Lv C; Sun B; Hong Q; Guo H
Tumour Biol; 2016 Apr; 37(4):5165-70. PubMed ID: 26547586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
